Tyra Biosciences (TYRA) Registration Filing summary

Company overview and business model

• Clinical-stage biotechnology company developing next-generation precision medicines for targeted oncology and genetically defined conditions, initially focused on FGFR biology.

• Utilizes an in-house precision medicine platform, SNÅP, to design small molecule drug candidates with high potency, selectivity, and tolerability.

• Lead programs include TYRA-300 (bladder cancer, skeletal conditions), TYRA-200 (intrahepatic cholangiocarcinoma), and TYRA-430 (hepatocellular carcinoma), all in clinical or preclinical development.

• Incorporated in Delaware in 2018, headquartered in Carlsbad, California.

Financial performance and metrics

• Net tangible book value as of March 31, 2025: $323.5 million, or $6.09 per share, with 53,089,957 shares outstanding.

• After a $150 million offering at $10.00 per share, adjusted net tangible book value would be $468.8 million, or $6.88 per share.

• Immediate dilution to new investors in the offering is estimated at $3.12 per share.

Use of proceeds and capital allocation

• Net proceeds will fund development of product candidates, preclinical and drug discovery programs, working capital, and general corporate purposes.

• Management has broad discretion in the application of proceeds, which may vary from current intentions.

• Pending use, proceeds may be invested in short- and intermediate-term, investment-grade, interest-bearing instruments.